Filing Flows › Companies › Halozyme Therapeutics › Earnings quality
Halozyme Therapeutics earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score67 / 100 · grade B · rank 466 of 1027
Halozyme Therapeutics (HALO) scores 67 of 100 for earnings quality, grade B: rank 466 of 1027 companies and 46 of 126 in health. It loses the most points on adjusted earnings 35% below GAAP, discretionary accruals of -21.8% of assets (modified Jones), larger than most, Montier C-score 3 of 6 checks failed. It earns full or near-full marks for accruals of -14.6% of assets, lower than 92% of companies (profit backed by cash), Beneish M-score -2.56: clean (below −2.22), Dechow F-score 0.77 (normal). Revenue grew 45% in the year: fast growth raises accruals, the Beneish and Dechow scores and the C-score by construction, so a growing company scores lower than a steady one with the same accounting.
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -14.6% of assets, lower than 92% of companies (profit backed by cash) | 18 | 20 |
| Beneish M-score | Beneish M-score -2.56: clean (below −2.22) | 15 | 15 |
| Dechow F-score | Dechow F-score 0.77 (normal) | 15 | 15 |
| Montier C-score | Montier C-score 3 of 6 checks failed | 8 | 15 |
| Discretionary accruals | discretionary accruals of -21.8% of assets (modified Jones), larger than most | 0 | 10 |
| Piotroski F-score | Piotroski F-score 5 of 9 | 6 | 10 |
| Non-GAAP gap | adjusted earnings 35% below GAAP | 0 | 10 |
| Earnings smoothness | profit about as variable as cash flow (smoothness 1.43) | 5 | 5 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Halozyme Therapeutics: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.